Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Paraganglioma

Paraganglioma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Paraganglioma

7 trials tracked for Paraganglioma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 183 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 6
  1. Phase 3 Preoperative Alpha Blockade for Pheochromocytoma Completed · 183 cited
  2. Phase 2 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Completed
  3. Phase 2 Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Completed
  4. Phase 2 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Completed
  5. Phase 2 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed
  6. Phase 2 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed
Show 1 more trials
  1. Phase 2 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Paraganglioma: what the trials found

Clinical evidence regarding the management of hemodynamic instability in patients with paraganglioma indicates that phenoxybenzamine was evaluated for this purpose. In a Phase 3 study, there was no statistically significant difference in the incidence of hemodynamic instability between the treatment groups (14 vs. 13; p=.56) 1.

Recent results — preliminary, needs further review

  • Cabozantinib (40 mg) was evaluated in a Phase 2 trial for paraganglioma, but results are not yet corroborated 2.
  • Sunitinib demonstrated a Clinical Benefit Rate (CBR), defined as PR, CR, or SD for ≥ 12 weeks, of 19 out of 25 patients 3.
  • Linsitinib showed a Clinical Benefit Rate (defined as SD ≥ 9 months, PR, or CR) in 40 out of 50 patients 6.
  • Axitinib (AG-013736) was evaluated in a Phase 2 trial 4.
  • Two separate trials investigated the use of MIBG isotopes (131I-MIBG and Ultratrace Iobenguane MIBG I 131) for this condition [5, 7].

For the clinician treating this condition

  • Phenoxybenzamine did not show a statistically significant difference in reducing hemodynamic instability compared to the control group in Phase 3 trials 1.
  • Multiple targeted therapies and radiopharmaceuticals (including Sunitinib, Linsitinib, Cabozantinib, Axitinib, and MIBG isotopes) are currently under investigation or have shown preliminary clinical benefit rates, but these findings are not yet corroborated as established standard evidence [2, 3, 4, 5, 6, 7].

AI synthesis of 5 cited trials, updated Jul 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SDHD Variant Carriers Face High Penetrance and Multifocal Tumors
Oncology Meta-analysis
SDHD Variant Carriers Face High Penetrance and Multifocal Tumors SDHD Genetic Variants Linked to Increasing Risk of Tumors Over Time
A meta-analysis of SDHD pathogenic variant carriers reveals age-specific penetrance rising to 82% by age 60, with 75% developing multifocal …
New data shows that the risk of developing tumors increases significantly with age for people carrying specific SDHD genetic variants.
Jul 26, 2026